MENU

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, RL; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; Licitra, L; Harrington, K; Kasper, S; Vokes, EE; Even, C; Worden, F; Saba, NF; Docampo, LCI; Haddad, R; Rordorf, T; Kiyota, N; Tahara, M; Monga, M; Lynch, M; Geese, WJ; Kopit, J; Shaw, JW; G

NEW ENGLAND JOURNAL OF MEDICINE
2016
VL / 375 - BP / 1856 - EP / 1867
abstract
BACKGROUND Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHODS In this randomized, open-label, phase 3 trial, we assigned, in a 2: 1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. RESULTS The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. CONCLUSIONS Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy.
72nd Global

AccesS level

Green Accepted

Mentions data

PAPER MENTIONS
Clinical Medicine
  •   Twitter
  • 305
  •   Wikipedia
  • 0
  •   News
  • 183
  •   Policy
  • 2
Global Ranking
  •   Twitter
  • 305
  •   Wikipedia
  • 0
  •   News
  • 183
  •   Policy
  • 2

Mentions Chart

Influratio by dimension
  • Twitter
  • Wikipedia
  • News
  • Policy
PAPER MENTIONS
  •   Twitter
  • 305
  •   Wikipedia
  • 0
  •   News
  • 183
  •   Policy
  • 2
PROYECTO FINANCIADO POR PLAN NACIONAL DE INVESTIGACIÓN AGENCIA ESTATAL DE INVESTIGACIÓN, MINISTERIO DE CIENCIA E INNOVACIÓN. PID2019-109127RB-I00